IUPAC Name: 2,3-Dihydroxybutanedioic acid ; 1-Methyl-2-[(E)-2-(3-methyl-2-thienyl)vinyl]-5,6-dihydro-4H-pyrimidine
Synonyms:Morantel tartrate ; Morantel tartrate hydrate
Product Categories: Alphabetic;Chemical Structure;M;METI - MZAntibiotics;Others
Molecular Structure of Morantel tartrate (CAS NO.26155-31-7) :
Molecular Formula of Morantel tartrate (CAS NO.26155-31-7) : C₁₂H₁₆N₂S.C₄H₆O₆
Molecular Weight of Morantel tartrate (CAS NO.26155-31-7) : 370.42
CAS NO: 26155-31-7
EINECS : 247-481-5
Mol File: 26155-31-7.mol
Flash Point: 156.1 °C
Enthalpy of Vaporization: 57.75 kJ/mol
Boiling Point: 334.6 °C at 760 mmHg
Vapour Pressure: 0.000127 mmHg at 25°C
Melting point:167-171°C

 Morantel tartrate (CAS NO.26155-31-7) is indicated (labeled) for the removal of the following para­sites in cattle .It is also used in other ruminant species

When heated to decomposition it emits acrid smoke and irritating fumes.
Hazard Codes Xn
Risk Statements 20/21/22
R20/21/22:Harmful by inhalation, in contact with skin and if swallowed.
Safety Statements 36 
S36:Wear suitable protective clothing.
WGK Germany 3
RTECS UW0246000

Storage/Stability/Compatibility - Morantel tartrate products should be stored at room temperature (15-30°C) unless otherwise instructed by the manufacturer.
Pharmacology - Like pyrantel, morantel acts as depolarizing neuromuscular blocking agent in susceptible parasites, thereby paralyzing the organism. The drug possesses nico­tine-like properties and acts similarly to acetylcholine. Morantel also inhibits fumarate re­ductase in Haemonchus spp.. Morantel is slower than pyrantel in its onset of action, but is approximately 100 times as potent.
Pharmacokinetics - After oral administration, morantel is absorbed rapidly from the up­per abomasum and small intestine. Peak levels occur about 4-6 hours after dosing. The drug is promptly metabolized in the liver. Within 96 hours of administration, 17% of the drug is excreted in the urine and the remainder in the feces.
Contraindications/Precautions - There are no absolute contraindications to using this drug. The sustained-release oral cartridges (Paratect®) are not to be used in cattle weigh­ing less than 90 kg. Morantel is considered to be generally safe to use during pregnancy.
Adverse Effects/Warnings - At recommended doses, adverse effects are not commonly seen. For more information, see Overdosage section below.
Overdosage/Acute Toxicity - Morantel tartrate has a large safety margin. In cattle, dosages of up to 200 mg/kg (20 times recommended dose) resulted in no toxic reactions. The LD50 in mice is 5 g/kg. Symptoms of toxicity that might possibly be seen include in­creased respiratory rates, profuse sweating (in animals able to do so), ataxia or other cholinergic effects.
Chronic toxicity studies have been conducted in cattle and sheep. Doses of 4 times rec­ommended were given to sheep with no detectable deleterious effects. Cattle receiving 2.5 times recommended dose for 2 weeks showed no toxic signs.
Drug Interactions - Paratect® cartridges should not be administered with mineral bul­lets as decreased anthelmintic efficacy can result. Because of similar mechanisms of action (and toxicity), morantel is recommended not to be used concurrently with pyrantel or levamisole. Observation for adverse effects should be intensified if used concomitantly with an organophosphate or diethylcarbamazine. Piperazine and morantel have antagonistic mechanisms of action; do not use together. Do not add to feeds containing bentonite.